News and Comments


  Thursday, October 22, 2015

The FDA issued a warning that hepatitis C treatment Viekira Pak and Technivie can cause serious side effects and serious liver injury, mostly in patients with underlying advanced liver disease.  More...

The Stream of Exelixis Good News is Real

  Thursday, October 22, 2015


Sarepta Versus Biomarin: Trying to make an Educated Guess

  Monday, October 19, 2015

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to decide upon reviewing Biomarin’s (BMRN) Duchenne muscular dystrophy (DMD) drug Drisapersen a few weeks earlier than reviewing Sarepta (SRPT) DMD drug Eteplirsen.  More...

Incyte And Merck Agree to Expand Their agreement Regarding their Immunotherapy Combination Drugs

  Tuesday, October 13, 2015


Yesterday Market Performance Brings Back Hope in Normalcy. Compugen Announced Some Encouraging News.

  Thursday, October 08, 2015

Stories From Yesterday Market More...

XOMA: A New Chance for Resurrection?

  Friday, October 02, 2015
  • - Exclusively licenses global rights to its (TGFb) antibody program to Novartis 
  •  More...

EXELIXIS: The Stream Of Good News Continues to Flow

  Monday, September 28, 2015

Exelixis (EXEL) announced positive results from the METEOR Phase 3 Pivotal Trial of Cabozantinib in advanced renal cell carcinoma, which was presented at the European Cancer Congress 2015. In the study, Cabozantinib met the primary endpoint of improving progression-free survival as compared to Evorulimus.  More...

Aerie Pharmaceuticals: Another Step Forward Towards the Approval of A Promising Glaucoma Drug

  Thursday, September 17, 2015

Aerie Pharmaceuticals (AERI), which is specialized in glaucoma treatments reported successful results of its second Phase 3 trial for Rhopressa™ — a novel once-daily, triple-action eye drops for glaucoma.   More...

Huge Improvement in the Differential Diagnosis of Diseases and More

  Wednesday, September 02, 2015

Biotechnology industry is proving to be the most innovative and the most growing among WallStreet industries. Individual biotech companies’ achievements complement each other. Some are evolving the sequencing of genes and genetic analysis, while others are excelling in designing drugs based on the tremendous amount of facts they are getting on root causes of the diseases and the interaction of proteins. The biotech companies have largely improved their drug discovery, design and development, including clinical trial plans and strategies.   More...

Why Switzerland Approval of Exelixis and Roche Drug Combination for melanoma is a Big Deal?

  Thursday, August 27, 2015


Recent Postings



Editas (EDIT) PTC Therapeutics (PTCT) ISIS (ISIS) Prosensa (RNA) Vitae Pharmaceuticals (VTAE) Velcade (bortezomib) Vertex (VRTX) Human Longevity (HLI) ImmunoGen (IMGN) Gilead (GILD) Xoma (XOMA) NEKTAR (NKTR)) PORTOLA (PTLA) Revlimid (lenolidamide) Trastuzumab-DM1 Intercept (ICPT) INNOVIVA (INVA) Intrexon (XON) REGULUS (RGLS) CompuGen (CGEN) Illumina (ILMN) Zerenex Biogen Idec (BIIB) Merck (MRK) Sanofi (SNA) Incyte (INCY) Anadys (ANDS) IDERA (IDRA) Herceptin Theravance Bio Pharma (TBPH) MODERNA Cytokinetics (CYTK) Regeneron (REGN) Spike Therapeutics (ONCE) Adaptimmune (ADAP) Auspex (ASPX) C4 Therapeutics ADVENTRIX (ANX) KITE (KITE) Rapamune NOVOCURE (NVCR) SERES THERAPEUTICS (MCRB) CEMPRA (CEMP) SYNTA (SNTA) Prolor Biotech (PBTH) Galena (GALE) Roche (ROCHE) HALOZYME (HALO) OSI (OSIP) VANDA (VNDA) Agenus (AGEN Jazz Pharmaceuticals (JAZZ) Amgen (AMGN) Biocryst (BCRX) SUNESIS PHARMACEUTICALS (SNSS) Seattle Genetics (SGEN) Ariad (ARIA) Micromet (MITI) CRISPR Therapeutics (CRSP) Array Pharmaceuticals (ARRY) AERIE PHARMACEUTICALS JUNO (JUNO) Agenus (AGEN) Multiple Myeloma Dendreon (DNDN) Exelixis (EXEL) Genentech Elan (ELN) AGOS (ARGS) Sarepta (SRPT) ABBVIE (ABBV) Bellicum (BLCM) Ionis (IONS) Onyx (ONXX) Tysabri Inovio (INO) Telaprevir TOKAI (TKAOI) Bristol-Myers Squibb (BMY) Pluristem (PSTI) Ziofpharm (ZIOP) ACADIA (ACAD) ARGOS (ARGS) Anacor (ANAC) RenenxBio (RGNX) Ocular Therapeutix (OCUL) GlaxoSmithKline (GSK) ARCA (ABIO) Advaxis (ADXS) KERYX (KERX) GUARDIAN HEALTH Benlysta (belimumab) Theravance (THRX) Alnylam (ALNY) JOUNCE THERAPEUTICS (JNCE) AstraZeneca (AZN) Sanofi-Aventis (SAN) NANTKWEST (NK) Human Genome Sciences (HGSI) Roche (RHHBY) Sanofi (SNY) Abbott Laboratories (ABT) Sangamo (SGMO) Dynavax (DVAX) Aimmune Therapeutics (AIMT) Mirati Therapeutics (MRTX) Intermune (ITMN) Global Cell Therapeutics (GBT) Valeant Pharmaceuticals International (VRX) Alder Biopharmaceuticals (ALDR) BIOMARIN (BMRN) Ridaforolimus Endometrial Cancer ZALTRAP™ galapagos (GLPG) Idenix (IDIX) Sequenom (SQNM)